GDF-15 is increased during early reperfusion following aortic valve replacement

Scandinavian Cardiovascular Journal

Volumn 46, Issue 2, 2012, Pages 99-106

  Majak, Peter ^a,b   Braathen, Bjørn ^a   Bjørnstad, Johannes L ^a,b,c   Tønnessen, Theis ^a,b,c  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

AVR; cardioplegia; GDF 15; IL 18; ischemia reperfusion

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 18;

ADULT; AGED; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; CARDIOPLEGIA; CLINICAL ARTICLE; CORONARY SINUS; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIAL ARTERY; REPERFUSION;

AGED; ANALYSIS OF VARIANCE; AORTIC VALVE; AORTIC VALVE STENOSIS; CARDIOPULMONARY BYPASS; CARDIOTONIC AGENTS; CORONARY SINUS; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INTERLEUKIN-16; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION; POTASSIUM COMPOUNDS; RADIAL ARTERY; STATISTICS AS TOPIC; TIME FACTORS;

EID: 84858428490     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431.2011.649489     Document Type: Article

References (35)

1. Heineke J, Kempf T, Kraft T, Hilfiker A, Morawietz H, Scheubel RJ, et al. Downregulation of cytoskeletal muscle LIM protein by nitric oxide: Impact on cardiac myocyte hypertrophy. Circulation. 2003;107:1424-32.
2. Tonnessen T, Giaid A, Saleh D, Naess PA, Yanagisawa M, Christensen G. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res. 1995;76:767-72.
3. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006;98: 351-60.
4. Woldbaek PR, Tonnessen T, Henriksen UL, Florholmen G, Lunde PK, Lyberg T, et al. Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc Res. 2003;59:122-31.
5. Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: Observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011;31:203-210.
6. Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: Update 2010. Am Heart J. 2010;160:583-94.
7. Venkatachalam K, Prabhu SD, Reddy VS, Boylston WH, Valente AJ, Chandrasekar B. Neutralization of interleukin-18 ameliorates ischemia/reperfusion-induced myocardial injury. J Biol Chem. 2009;284:7853-65.
8. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA. 1997;94:11514-9.
9. Ago T, Sadoshima J. GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res. 2006;98:294-7.
10. Kempf T, Wollert KC. Growth-differentiation factor-15 in heart failure. Heart Fail Clin. 2009;5:537-47.
11. Schlittenhardt D, Schober A, Strelau J, Bonaterra GA, Schmiedt W, Unsicker K, et al. Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res. 2004;318:325-33.
12. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006;98:342-50.
13. Kempf T, Bjorklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007;28:2858-65.
14. Wollert KC. Growth-differentiation factor-15 in cardiovascular disease: From bench to bedside, and back. Basic Res Cardiol. 2007;102:412-5.
15. Wollert KC, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Allhoff T, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation. 2007;116:1540-48.
16. Bjornstad JL, Neverdal NO, Vengen OA, Knudsen CW, Husebye T, Pepper J, et al. Alterations in circulating activin A, GDF-15, TGF-beta3 and MMP-2, -3, and -9 during one year of left ventricular reverse remodelling in patients operated for severe aortic stenosis. Eur J Heart Fail. 2008; 10:1201-1207.
17. Hartford M, Wiklund O, Hulten LM, Persson A, Karlsson T, Herlitz J, et al. Interleukin-18 as a predictor of future events in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2010;30:2039-46.
18. Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, et al. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart. 2002; 88:467-9.
19. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for atherogenesis. J Exp Med. 2002;195:245-57.
20. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res. 2001;89:E41-E45.
21. Welsh P, Woodward M, Rumley A, MacMahon S, Lowe GD. Does interleukin-18 or tumour necrosis factor-alpha have an independent association with the risk of coronary heart diseasě Results from a prospective study in New Zealand. Cytokine. 2010;50:94-8.
22. Woldbaek PR, Sande JB, Stromme TA, Lunde PK, Djurovic S, Lyberg T, et al. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol. 2005;289:H708-H714.
23. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M, et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A. 2000;97:1190-95.
24. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, et al. Interleukin-18 and the risk of coronary heart disease in European men: The prospective epidemiological study of myocardial infarction (PRIME). Circulation. 2003;108:2453-9.
25. Thompson SR, McCaskie PA, Beilby JP, Hung J, Jennens M, Chapman C, et al. IL18 haplotypes are associated with serum IL-18 concentrations in a population-based study and a cohort of individuals with premature coronary heart disease. Clin Chem. 2007;53:2078-2085.
26. Majak P, Bjornstad J, Vengen OA, Neverdal NO, Husebye T, Woldbaek P, et al. Plasma IL-18 and IL-18BP are altered differently in reverse remodeling following aortic valve replacement. Scand Cardiovasc. J 2010;44:113-8.
27. Braathen B, Tonnessen T. Cold blood cardioplegia reduces the increase in cardiac enzyme levels compared with cold crystalloid cardioplegia in patients undergoing aortic valve replacement for isolated aortic stenosis. J Thorac Cardiovasc. Surg 2010;139:874-80.
28. Ferguson ER, Spruell RD, Vicente WV, Murrah CP, Holman WL. Coronary vascular regulation during postcardioplegia reperfusion. J Thorac Cardiovasc Surg. 1996;112: 1054-1063.
29. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;115:962-71.
30. Eggers KM, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Jantzen F, et al. Growth-differentiation factor-15 for longterm risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet. 2010;3:88-96.
31. Thompson SR, Novick D, Stock CJ, Sanders J, Brull D, Cooper J, et al. Free Interleukin (IL)-18 levels, and the impact of IL18 and IL18BP genetic variation, in CHD patients and healthy men. Arterioscler Thromb Vasc Biol. 2007;27:2743-9.
32. Wu HY, Li F, Tang QF. Immunological effects of laparoscopic and open cholecystectomy. J Int Med Res. 2010; 38:2077-2083.
33. Zahler S, Massoudy P, Hartl H, Hahnel C, Meisner H, Becker BF. Acute cardiac inflammatory responses to postischemic reperfusion during cardiopulmonary bypass. Cardiovasc Res. 1999;41:722-30.
34. Kerbaul F, Collard F, Benard F, By Y, Paganelli F, Saadjian A, et al. Release of markers of myocardial damage evaluated in the coronary sinus during cardiac surgery. J Investig Med. 2007;55:195-201.
35. Mantovani V, Kennergren C, Bugge M, Sala A, Lonnroth P, Berglin E. Myocardial metabolism assessed by microdialysis: A prospective randomized study in on- and offpump coronary bypass surgery. Int J Cardiol. 2010;143: 302-308.